ADHD Shared Care Agreements: What Patients Need to Know in the UK

An ADHD shared care agreement in the UK is one of the most important - and most misunderstood - aspects of ongoing ADHD treatment. Over the past two years, shared care has become a point of growing confusion for patients, GPs, and private providers alike.

Patients often assume that once they receive a diagnosis, NHS prescribing will naturally follow. GPs, meanwhile, are navigating increasing pressure around controlled medications, local commissioning rules, and workload constraints. Private providers operate under different models, with varying documentation standards and prescribing structures.

The result is uncertainty. Shared care was originally designed to integrate specialist treatment into community care smoothly. In ADHD treatment, however, the process has become more complex - and sometimes a source of tension.

This article explores how ADHD shared care agreements work, why friction is emerging, and what patients should understand before starting treatment.

The Rise of Private ADHD Diagnosis

ADHD referrals in the UK have increased significantly in recent years. In many regions, NHS waiting times for assessment now exceed 12 months, though this varies considerably by area - some services are shorter, while others extend well beyond two years.

As a result, more patients are exploring alternative pathways:

• NHS-funded Right to Choose pathways, which allow patients in England to request assessment from an approved provider outside the NHS. It is worth noting that this policy area has been subject to ongoing review, and patients should verify its current status with their local Integrated Care Board before relying on it
• Private ADHD assessments, which offer shorter waiting times but require careful planning around prescribing
• Hybrid models of care, combining private diagnosis with NHS-funded ongoing treatment

Private assessment can reduce waiting times significantly. However, prescribing ADHD medication - particularly stimulant medication - requires careful coordination between specialist and GP.

This is where shared care becomes central.

What Is an ADHD Shared Care Agreement?

A shared care agreement is a formal arrangement between three parties:

• A specialist clinician, usually a psychiatrist
• A GP
• The patient

In ADHD treatment, the specialist diagnoses and initiates medication, completing a process called titration to achieve a stable and effective dose. Once stable, the GP may take over repeat prescribing under agreed monitoring protocols.

In theory, this allows:

• Specialist-led diagnosis and initiation
• Local GP monitoring and ongoing prescribing
• Access to NHS prescription pricing
• Reduced long-term private costs

It is worth clarifying that NHS prescriptions are not necessarily free. The standard NHS prescription charge applies unless the patient qualifies for an exemption - for example, on grounds of low income, certain medical conditions, or age. For most adults, each NHS prescription item carries a charge.

Shared care is common in other areas of medicine. In ADHD, however, implementation has become more complex than many patients expect.

Managing ADHD Prescription Costs: Prepayment Certificates

For patients on ongoing ADHD medication, prescription costs can accumulate quickly - particularly if multiple items are prescribed each month.

A Prescription Prepayment Certificate (PPC) allows patients in England to pay a fixed amount for unlimited NHS prescriptions over a set period. A 12-month certificate currently costs around £111.60, which is often significantly cheaper than paying per item.

PPCs are available from the NHS Business Services Authority and can be purchased online. They are worth considering for any patient collecting ADHD medication regularly, as the savings can be substantial over the course of a year.

Where Friction Is Emerging in ADHD Shared Care

Several structural factors contribute to confusion around ADHD shared care agreements.

1. Variation Between Regions

In England, Integrated Care Boards (ICBs) may issue local guidance affecting whether shared care is accepted from certain providers. Policies are not always uniform across the country, and some ICBs have introduced restrictions or pauses that affect specific pathways.

2. Documentation Standards

GPs rely on clear, comprehensive assessment reports, medication plans, and shared care protocols from the diagnosing specialist. Where documentation varies in depth or structure, uncertainty can arise - and GPs may feel unable to accept prescribing responsibility.

3. Controlled Medication Considerations

ADHD stimulant medications such as methylphenidate and lisdexamfetamine are classified as controlled drugs. Prescribing carries regulatory responsibility. Some GPs feel cautious about assuming this responsibility without strong, ongoing specialist oversight.

4. Workload Pressures

Primary care services are under significant strain. Taking on additional prescribing complexity - including regular monitoring, dose reviews, and controlled drug management - can feel difficult to absorb, even when clinically appropriate.

These factors mean shared care decisions are often influenced by local policy, documentation quality, and workload realities - not just clinical judgement alone.

Why a GP Declining Shared Care Feels Personal - But Often Isn't

When a GP declines shared care, patients can feel:

• Rejected
• Invalidated
• As though their diagnosis is being questioned

In most cases, however, the issue is structural rather than personal. Shared care agreements are voluntary for GPs. A GP cannot be required to enter into one. A refusal does not invalidate a diagnosis - it affects the prescribing pathway, not the clinical finding.

Understanding this distinction is important. If your GP declines, it is worth asking whether they can explain the reason and whether there is an alternative route - such as referring you to an NHS psychiatrist who can take over prescribing.

The Impact on Patients

The uncertainty around shared care has practical consequences:

• Ongoing private prescription costs, which can be significantly higher than NHS charges
• Delays in accessing medication after diagnosis
• Anxiety around treatment continuity
• Confusion about next steps, particularly when different professionals give different guidance

It also means that the pathway chosen at the assessment stage can directly influence long-term prescribing options. A provider whose shared care documentation is thorough may offer a smoother transition to GP prescribing than one whose processes are less structured.

Clarity before starting treatment is increasingly important.

A System in Transition

ADHD demand has increased faster than service capacity in many areas of the UK. At the same time, public and private pathways have become more interconnected:

• NHS-funded assessments delivered by independent providers
• Private assessments followed by NHS prescribing under shared care
• Hybrid care arrangements combining specialist and GP involvement

Shared care sits at the intersection of these systems. As demand grows, clearer communication between specialists, GPs, and patients will be essential to reduce uncertainty and improve outcomes.

Looking Ahead: ADHD Shared Care Agreements in the UK

ADHD shared care agreements remain an established and important part of treatment in the UK. When documentation is thorough, titration is complete, and communication between specialist and GP is clear, shared care can function effectively.

However, in 2026, prescribing is no longer something patients can assume will automatically follow diagnosis. It is a structured arrangement that depends on clinical clarity, local policy, and collaboration between professionals.

Understanding this landscape helps reduce anxiety - and supports more informed decisions about ADHD assessment and treatment pathways. If you are comparing ADHD assessment options, knowing how prescribing and shared care work is an important step in choosing the right pathway for your situation.